| Literature DB >> 33072833 |
M Mofijur1, I M Rizwanul Fattah1, Md Asraful Alam2, A B M Saiful Islam3, Hwai Chyuan Ong1, S M Ashrafur Rahman4, G Najafi5, S F Ahmed6, Md Alhaz Uddin7, T M I Mahlia1.
Abstract
COVID-19 has heightened human suffering, undermined the economy, turned the lives of billions of people around the globe upside down, and significantly affected the health, economic, environmental and social domains. This study aims to provide a comprehensive analysis of the impact of the COVID-19 outbreak on the ecological domain, the energy sector, society and the economy and investigate the global preventive measures taken to reduce the transmission of COVID-19. This analysis unpacks the key responses to COVID-19, the efficacy of current initiatives, and summarises the lessons learnt as an update on the information available to authorities, business and industry. This review found that a 72-hour delay in the collection and disposal of waste from infected households and quarantine facilities is crucial to controlling the spread of the virus. Broad sector by sector plans for socio-economic growth as well as a robust entrepreneurship-friendly economy is needed for the business to be sustainable at the peak of the pandemic. The socio-economic crisis has reshaped investment in energy and affected the energy sector significantly with most investment activity facing disruption due to mobility restrictions. Delays in energy projects are expected to create uncertainty in the years ahead. This report will benefit governments, leaders, energy firms and customers in addressing a pandemic-like situation in the future.Entities:
Keywords: Coronavirus vaccine; Environmental pollution; Global Pandemic; NO2 emission; PM emission; SARS-CoV-2; Waste generation
Year: 2020 PMID: 33072833 PMCID: PMC7556229 DOI: 10.1016/j.spc.2020.10.016
Source DB: PubMed Journal: Sustain Prod Consum ISSN: 2352-5509
Fig. 1The initial stage development timeline for COVID-19 (Yan et al., 2020).
Fig. 2Infections and replication cycle of the coronavirus (Acter et al., 2020).
Fig. 3Initial preventive measures to lower the COVID-19 outbreak (Bruinen de Bruin et al., 2020).
Fig. 4Global transport and aviation activity in the first quarter of the year 2020 (International Energy Agency (IEA), 2020).
Fig. 5The lifespan of SARS-CoV-2 on different media (Chin et al., 2020; van Doremalen et al.; 2020; Ye et al., 2016)
Fig. 6Recommended waste management during COVID-19 (ACR+ 2020).
NO2 emissions data acquisition by ESA using Sentinel-5P across different regions of Europe (Financial Times, 2020).
| Country | Initial data | Final data | % reduction |
|---|---|---|---|
| Europe | March 2019 | March 2020 | Up to 30% |
| Italy | March 2019 | March 2020 | Up to 30% |
| France | March 2019 | March 2020 | Up to 30% |
| Spain | March 2019 | March 2020 | Up to 30% |
| UK | January 2020 | March 2020 | Up to 36% |
Fig. 7Comparison of the NO2 concentration between 2019 and 2020 in Europe (European Space Agency (ESA), 2020).
Fig. 8Changes in average NO2 emission in different countries (Myllyvirta, 2020).
Fig. 9Changes of NO2 emission (a) over entire Italy (b) capital city (c) other cities (European Space Agency (ESA), 2020; Atmosphere Monitoring Service, 2020).
Fig. 10Comparison between before and after lockdown NO2 emissions in Spain (European Space Agency (ESA), 2020).
Fig. 11Comparison of NO2 emissions in France before and after lockdown (European Space Agency (ESA), 2020).
Fig. 12(a) Changes in NO2 emissions in the UK during lockdown (European Space Agency (ESA), 2020); (b) comparison of NO2 emissions in 2019 and 2020 (Khoo, 2020).
Fig. 13Reduction of PM emission in different countries (Myllyvirta, 2020).
Fig. 14Comparison of PM emission in Italy (a) PM2.5 emission (b) Changes of PM2.5 emission (c) PM10 emission (d) Changes of PM10 emission (Sicard et al., 2020).
Fig. 15(a) Quarterly World GDP. 2019:Q1 =100, dashed line indicates estimates from January 2020 WEO; (b) GDP fall due to lockdown in selected countries.
Impact of COVID-19 on global energy sector (AEMO, 2020; CIS Editorial, 2020; Eurelectric, 2020; Livemint, 2020; Renewable Energy World, 2020; S&P Global, 2020; Madurai Elavarasan et al., 2020).
| Country | Lockdown start | Lockdown end | Energy demand |
|---|---|---|---|
| Australia | 23rd March 2020 | 15th May 2020 (Stage 1, for NSW) | NSW: Weekday: 8%–10%↓ (morning) 6%–8%↓ (afternoon) Weekend: 5%–6%↓ (most of the day) |
| Belgium | 18th March 2020 | 19th April 2020 | Substantial ↓ in the industrial and commercial load of 70% |
| China | 23rd January 2020 | 8th April 2020 | 8%↓ (Jan & Feb compared to the same time in 2019) |
| France | 17th March 2020 | 11th May 2020 | 6%–12%↓ (electricity demand) |
| Germany | 20th March 2020 | 20th April 2020 | 4%–6% ↓ (electricity demand) |
| India | 25th March 2020 | 4th May 2020 | 30%↓ |
| Italy | 9th March 2020 | 4th May 2020 | 10.1%↓ (March) 22%↓(from 22nd March) |
| Portugal | 13th March 2020 | 11th April 2020 | Overall energy demand ↓ |
| Singapore | 7th April 2020 | 1st June 2020 | 8%–9%↓ |
| Spain | 14th March 2020 | 25th April 2020 | 3%↓ (March) 20%↓ (April), 72%↑ (PV generation) |
| Netherlands | 16th March 2020 | 28th April 2020 | Overall energy demand ↓ |
| UK | 24th March 2020 | 11th May 2020 | 10%↓ (after 23rd March) |
| US | 20th March 2020 | 29th April 2020 | 4.2% ↓ (retail sales of electricity) |
Mobility index report of different countries (Ghosh, 2020; Johns Hopkins University (JHU), 2020; Worldometer, 2020).
| Country | Total population | Mobility rate | Recovery rate | Total Cases | Total recovered |
|---|---|---|---|---|---|
| Argentina | 45,195,774 | -56% | 42.63% | 153,520 | 65,447 |
| Australia | 25,499,884 | -41% | 64.02% | 13,948 | 8,929 |
| Austria | 9,006,398 | -100% | 89.11% | 20,338 | 18,124 |
| Belgium | 11,589,623 | -105% | 26.68% | 65,199 | 17,394 |
| Brazil | 212,559,417 | -48% | 67.81% | 2,348,200 | 1,592,281 |
| Canada | 37,742,154 | -67% | 87.34% | 113,206 | 98,873 |
| Chile | 19,116,201 | -110% | 91.91% | 341,304 | 313,696 |
| Colombia | 50,882,891 | -73% | 48.76% | 233,541 | 113,864 |
| Czech Republic | 10,708,981 | -29% | 62.48% | 15,081 | 9,422 |
| Denmark | 5,792,202 | -93% | 91.83% | 13,438 | 12,340 |
| Finland | 5,540,720 | -93% | 93.67% | 7,388 | 6,920 |
| France | 65,273,511 | -100% | 44.77% | 180,528 | 80,815 |
| Germany | 83,783,942 | -99% | 92.44% | 205,968 | 190,400 |
| Greece | 10,423,054 | -32% | 33.23% | 4,135 | 1,374 |
| Hong Kong | 7,496,981 | -10% | 59.29% | 2,373 | 1,407 |
| Hungary | 9,660,351 | -49% | 75.14% | 4,424 | 3,324 |
| India | 1,380,004,385 | -65% | 63.49% | 1,339,176 | 850,303 |
| Indonesia | 273,523,615 | -77% | 56.90% | 97,286 | 55,354 |
| Ireland | 4,937,786 | -79% | 90.40% | 25,845 | 23,364 |
| Israel | 8,655,535 | -31% | 45.06% | 59,475 | 26,797 |
| Italy | 60,461,826 | -52% | 80.70% | 245,590 | 198,192 |
| Japan | 126,476,461 | -33% | 76.29% | 27,956 | 21,328 |
| Malaysia | 32,365,999 | -53% | 96.74% | 8,884 | 8,594 |
| Mexico | 128,932,753 | -69% | 64.16% | 378,285 | 242,692 |
| Netherlands | 17,134,872 | -97% | 11.65% | 52,837 | 6,158 |
| New Zealand | 4,822,233 | -21% | 97.24% | 1,556 | 1,513 |
| Norway | 5,421,241 | -100% | 95.40% | 9,092 | 8,674 |
| Philippines | 109,581,078 | -87% | 32.84% | 78,412 | 25,752 |
| Poland | 37,846,611 | -36% | 76.06% | 42,622 | 32,419 |
| Portugal | 10,196,709 | -65% | 69.80% | 49,692 | 34,687 |
| Singapore | 5,850,342 | -105% | 90.55% | 49,888 | 45,172 |
| South Africa | 59,308,690 | -74% | 58.24% | 421,996 | 245,771 |
| South Korea | 51,269,185 | -4% | 91.30% | 14,092 | 12,866 |
| Spain | 46,754,778 | -67% | 47.07% | 319,501 | 150,376 |
| Switzerland | 8,654,622 | -101% | 88.92% | 34,302 | 30,500 |
| Taiwan | 23,816,775 | 4% | 96.07% | 458 | 440 |
| Thailand | 69,799,978 | -36% | 94.73% | 3,282 | 3,109 |
| USA | 331,002,651 | -56% | 47.74% | 4,248,759 | 2,028,361 |
| UK | 67,886,011 | -82% | 0.48% | 297,914 | 1,427 |
| Vietnam | 97,338,579 | 15% | 87.53% | 417 | 365 |
List of vaccines that have passed the pre-clinical stage (Biorender, 2020).
| Name | Organisation | Technology | Stage | Clinical Trial # |
|---|---|---|---|---|
| Oral Polio Vaccine | Bandim Health Project | Repurposed | Phase IV | NCT04445428 |
| Bacille Calmette-Guerin | Multiple Organisations | Repurposed | Phase III/IV | NCT04328441 |
| Measles-Mumps-Rubella Vaccine | Multiple Organisations | Repurposed | Phase III | NCT04357028 |
| IMM-101 | Multiple Organisations | Repurposed | Phase III | NCT04442048 |
| BACMUNE (MV130) | Inmunotek S.L., BioClever 2005 S.L. | Repurposed | Phase III | NCT04452643 |
| mRNA-1273 | Multiple Organisations | RNA-based vaccine | Phase I/II/III | NCT04283461 |
| CoronaVac | Sinovac Biotech Co., Butantan Institute | Inactivated virus | Phase I/II/III | NCT04352608 |
| AZD1222 (ChAdOx1 nCoV-19) | Multiple Organisations | Non-replicating viral vector | Phase I/II/III | NCT04324606 |
| NasoVAX | Altimmune, Inc. | Repurposed | Phase II | NCT04442230 |
| LV-SMENP-DC | Shenzhen Geno-Immune Medical Institute | Modified APC | Phase I/II | NCT04276896 |
| Ad5-nCoV | Multiple Organisations | Non-replicating viral vector | Phase I/II | NCT04313127 |
| INO-4800 | Multiple Organisations | DNA-based | Phase I/II | NCT04336410 |
| Unnamed Inactive Vaccine - Wuhan | Wuhan Institute of Biological Products, Sinopharm | Inactivated virus | Phase I/II | ChiCTR2000031809 |
| BBIBP-CorV | Beijing Institute of Biological Products, Sinopharm | Inactivated virus | Phase I/II | ChiCTR2000032459 |
| BNT162 (a1, b1, b2, c2) | Biontech RNA Pharmaceuticals GmbH, Pfizer | RNA-based vaccine | Phase I/II | EudraCT 2020-001038-36 |
| KBP-COVID-19 | Kentucky BioProcessing, Inc. | Protein subunit | Phase I/II | NCT04473690 |
| LUNAR-COV19 (ARCT-021) | Arcturus Therapeutics, Inc., Duke-NUS | RNA-based vaccine | Phase I/II | NCT04480957 |
| COVAC 1 | Imperial College London, Morningside Ventures | RNA-based vaccine | Phase I/II | IRAS-Number: 279315 |
| AG0301-COVID19 | AnGes, Inc.,Japan Agency for Medical Research and Development | DNA-based | Phase I/II | NCT04463472 |
| V-SARS | Immunitor LLC | Inactivated virus | Phase I/II | NCT04380532 |
| AV-COVID-19 | Aivita Biomedical, Inc. | Modified APC | Phase I/II | NCT04386252 |
| Unnamed Inactive Vaccine - Yunnan | Multiple Organisations | Inactivated virus | Phase I/II | NCT04412538 |
| Gam-COVID-Vac | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation, Acellena Contract Drug Research and Development | Non-replicating viral vector | Phase I/II | NCT04437875 |
| AlloStim | Immunovative Therapies, Ltd., Mirror Biologics, Inc. | Other | Phase I/II | NCT04441047 |
| GX-19 | Genexine, Inc. | DNA-based | Phase I/II | NCT04445389 |
| BBV152A, B, C | Bharat Biotech International Limited,Indian Council of Medical Research | Inactivated virus | Phase I/II | NCT04471519 |
| bacTRL-Spike | Multiple Organisations | DNA-based | Phase I | NCT04334980 |
| NVX-CoV2373 | Novavax | Protein subunit | Phase I | NCT04368988 |
| COVID-19/aAPC Vaccine | Shenzhen Geno-Immune Medical Institute | Modified APC | Phase I | NCT04299724 |
| Unnamed VLP Vaccine | Medicago Inc. | Virus-like particle | Phase I | NCT04450004 |
| CVnCoV | CureVac AG, Coalition for Epidemic Preparedness Innovations (CEPI) | RNA-based vaccine | Phase I | NCT04449276 |
| SCB-2019 | Clover Biopharmaceuticals | Protein subunit | Phase I | NCT04405908 |
| COVAX-19 | Multiple Organisations | Protein subunit | Phase I | NCT04428073 |